Myositis Management in Peshawar

fjsfjfszj

Inflammatory Muscle Disease Specialist — Peshawar & KPK

Myositis Management in Peshawar

Progressive muscle weakness that makes rising from the floor, climbing stairs, or lifting objects increasingly difficult — without any injury to explain it — is one of the most alarming symptoms a patient in Peshawar can experience, and one of the least likely to be correctly diagnosed in a timely way. Myositis is an inflammatory muscle disease caused by the immune system attacking the body’s own muscle tissue, and it is routinely missed in KPK because it mimics neurological disease, is attributed to generalised weakness or anaemia, and requires specialised blood tests that are not routinely ordered.

⚠️ Symptoms that may indicate myositis:

Difficulty rising from the floor or a low chair without using your arms
Progressive weakness climbing stairs or walking uphill
Difficulty lifting arms above the head — combing hair, reaching shelves
Muscle aching or tenderness, particularly in the shoulders and hips
Unexplained fatigue and general weakness over weeks to months
Skin changes on the knuckles, eyelids, or upper chest (in dermatomyositis)
Difficulty swallowing solid food or choking more easily than before

Getting it right from the start is what OAIC does differently — Dr Inam’s Certificate in Rheumatology from AACME USA provides the clinical framework to identify, stage, and manage myositis correctly, distinguishing it from the conditions it is most commonly confused with.

15–25%

Of adult dermatomyositis cases are associated with an underlying malignancy

50+

Age group most commonly affected by inclusion body myositis (IBM)

10–50×

How far CK can rise above normal in active polymyositis or dermatomyositis

AACME USA

Source of Dr Inam’s Certificate in Rheumatology

The fundamental distinction

True inflammatory myositis and its common mimics are not the same disease

Most patients arrive having been told they have “muscle weakness” or “body aches” without being told which kind. Vitamin D deficiency, fibromyalgia, statin side effects, and neurological disease all produce overlapping symptoms — but they have different causes, different tests, and different treatments.

Progressive despite rest

True Inflammatory Myositis

Caused by the immune system attacking skeletal muscle directly. Weakness is genuine and objective — patients cannot perform the task, not merely find it painful.

Includes

Polymyositis

Dermatomyositis

Inclusion Body Myositis

Antisynthetase Syndrome

Often misattributed

Common Mimics in KPK

Several common, very treatable conditions produce similar symptoms and are frequently mistaken for myositis — or myositis is mistaken for them.

Includes

Vitamin D deficiency

Fibromyalgia

Motor neurone disease

Statin myopathy

Conditions treated at OAIC

Types of myositis managed in Peshawar

Myositis is not one disease — it is a family of related conditions, each with its own pattern, risks, and treatment response.

Most common adult form

Polymyositis (PM)

Progressive, symmetrical weakness of the shoulders, hips, and thighs developing over weeks to months. Markedly elevated CK with no skin involvement. Most common in women aged 30–60.

Skin + muscle

Dermatomyositis (DM)

Proximal weakness plus characteristic skin changes — Gottron’s papules, heliotrope rash. In adults, associated with an underlying malignancy in 15–25% of cases, triggering routine cancer screening at OAIC.

Treatment-resistant

Inclusion Body Myositis (IBM)

The most common inflammatory myopathy over age 50. Causes asymmetric weakness of the finger flexors and thighs, and is genuinely resistant to the treatments that work for PM and DM.

Paediatric

Juvenile Dermatomyositis (JDM)

Inflammatory myositis in children, almost always with skin involvement. Associated with calcinosis and joint contractures if not treated promptly.

Lung risk

Antisynthetase Syndrome

Defined by anti-Jo-1 and related antibodies. Causes the triad of myopathy, interstitial lung disease, and arthritis — the lung involvement is the main determinant of prognosis.

Reversible

Drug-Induced Myositis

Statins are the most common cause, ranging from simple myalgia to severe necrotising myopathy. Identifying and stopping the causative drug is often the most effective treatment.

The diagnostic process

How myositis is diagnosed at OAIC

A structured clinical assessment — not a single blood test in isolation.

01

Clinical history

The pattern of weakness is the most diagnostically important clue. Proximal weakness developing over weeks to months without injury — plus a detailed medication review for statins and other myotoxic drugs.

02

Physical examination

Manual muscle testing compares strength side to side and proximal versus distal. Dermatomyositis skin changes, lung auscultation, and joint examination are checked specifically.

03

Targeted blood tests

Not a blanket panel — specific tests chosen by clinical presentation:

Creatine kinase & aldolase — degree of active muscle breakdown
ANA & myositis-specific antibodies — Jo-1, Mi-2, MDA-5, SRP, TIF-1γ
TSH & Vitamin D — to exclude reversible causes of weakness
ESR & CRP — overall inflammatory activity

04

EMG & muscle MRI

Electromyography distinguishes inflammatory myopathy from neuropathy. Muscle MRI identifies active inflammation and guides the optimal site for biopsy.

05

Muscle biopsy & chest imaging

The definitive test when diagnosis is uncertain — confirms PM, DM, or the specific inclusions that define IBM. HRCT chest screens all newly diagnosed patients for interstitial lung disease.

Why patients choose OAIC

Why patients across KPK choose OAIC for myositis management

🔬 Certificate in Rheumatology — AACME USA

The diagnostic and management framework for myositis sits firmly within rheumatology. Dr Inam’s postgraduate qualification provides the clinical foundation to diagnose accurately and identify the associations that determine long-term outcomes.

🎓 FCPS • FRCS UK • FACS

The depth of general medical and surgical training that underlies the subspecialty rheumatology qualification — relevant when joint complications or surgical procedures are needed alongside myositis care.

🧬 Integrated connective tissue disease care

Myositis rarely occurs in isolation — it frequently overlaps with MCTD, systemic sclerosis, and Sjögren’s syndrome. These overlapping conditions are managed within a single practice at OAIC.

🩺 Malignancy screening as standard

All adult patients newly diagnosed with dermatomyositis at OAIC receive age-appropriate cancer screening as a standard, non-negotiable part of their initial workup.

⚖️ Rational steroid management

The treatment plan from the first consultation includes a structured pathway for steroid reduction and a defined second-line agent to permit it — avoiding the most common iatrogenic harm seen in KPK.

📍 Long-term follow-up, not episodic care

Myositis is chronic and relapsing. Regular monitoring of CK, blood counts, organ function, and respiratory status is coordinated longitudinally at OAIC — serving patients from across KPK.

Frequently Asked Questions

Q1: Who is the best myositis specialist in Peshawar?

Dr Muhammad Irfan Khan at OAIC holds FCPS, FRCS (UK), FACS, and a Certificate in Rheumatology from AACME USA — one of the very few specialists in KPK with formal rheumatology training specifically covering inflammatory muscle disease. He diagnoses and manages polymyositis, dermatomyositis, and other myositis syndromes, and includes body myositis at OAIC, alongside associated connective tissue disease that frequently overlap with myositis. He consults at Aabar Medical Centre, Peshawar, Monday to Friday from 4:00 PM.

Q2: What is myositis and how is it different from general muscle weakness?

Myositis is an autoimmune inflammatory disease in which the immune system attacks and destroys skeletal muscle fibres, causing progressive weakness — of the muscles of the shoulders, hips, and thighs are affected first. It differs from common causes of muscle weakness in Pakistan (Vitamin D deficiency, anaemia, deconditioning) because it’s progressive despite rest, causes markedly elevated creatine kinase in the blood, and does not improve without immunosuppressive treatment. Correctly identifying myositis prevents months or years of ineffective supplementation and permits the treatment that genuinely halts the disease.

Q3: How is myositis diagnosed in Peshawar?

Diagnosis at OAIC combines a detailed clinical history and muscle-strength examination with targeted blood tests — creatine kinase, aldolase, thyroid function, ANA, and myositis-specific antibodies — and electromyography when needed. Muscle MRI is used to identify active inflammation and guide biopsy. Muscle biopsy through LRH MTI confirms the histological diagnosis when the clinical and biochemical picture requires it. Chest imaging and pulmonary function tests screen for associated interstitial lung disease, which is present in a significant proportion of myositis patients.

Q4: Is myositis treatable? Can patients recover strength?

Yes — polymyositis and dermatomyositis respond well to immunosuppressive treatment in the majority of patients, particularly when treated early before significant muscle fibre destruction has occurred. Corticosteroids suppress the acute inflammation; methotrexate or azathioprine maintain remission at a lower steroid dose. Most patients regain significant strength with treatment, though recovery is measured in months, not weeks, and requires concurrent supervised physiotherapy once the disease is controlled. Inclusion body myositis is unfortunately more resistant to immunosuppressive treatments, which is why distinguishing it from PM early avoids exposing patients to ineffective medication with significant side effects.

Q5: Can myositis be treated in Peshawar without going to Lahore?

Yes. Diagnosis, initiation of immunosuppressive treatment, and ongoing monitoring of myositis and associated connective tissue diseases are all available at OAIC in Peshawar. For patients requiring biological therapy (rituximab, IVIG) or management of severe interstitial lung disease, Dr Irfan coordinates with appropriate specialist and infusion services while continuing to manage the overall condition from OAIC.

Q6: What is dermatomyositis and why is the skin important?

Dermatomyositis is a form of inflammatory myositis with characteristic skin changes — Gottron’s papules over the knuckles, heliotrope rash on the eyelids, and redness over the upper chest and back. These skin changes are diagnostically specific and, in the right clinical context, confirm the diagnosis before lesser tests are performed. They are important for a second reason: dermatomyositis in adults — particularly over age 40 — is associated with an underlying malignancy in 15–25% of cases. Any new diagnosis of dermatomyositis at OAIC triggers an age-appropriate cancer screening workup as a standard, non-negotiable component of initial management.

Q7: What happens if myositis is left untreated?

Untreated myositis causes progressive, irreversible muscle fibre destruction. The weakness advances from difficulty climbing stairs to inability to walk, rise from a chair, or lift the arms above the head, in dermatomyositis and antisynthetase syndrome, interstitial lung disease progresses in parallel — causing worsening breathlessness, reduced exercise capacity, and in severe cases respiratory failure. Swallowing difficulty from pharyngeal muscle involvement risks aspiration pneumonia. The cardiac muscle can be involved, causing arrhythmias and heart failure. None of these consequences are inevitable with correct early treatment — but all are possible without it.

Q8: My child has muscle weakness and rash — could it be myositis?

Dermatomyositis in children (juvenile dermatomyositis) is a rare but serious condition that requires prompt diagnosis. The combination of proximal muscle weakness and skin changes — particularly Gottron’s papules over the knuckles or periorbital rash — in a child should be assessed by a specialist without delay. JDM requires early treatment to prevent calcinosis (calcium deposits in muscle and skin) and joint contractures, which are the most disabling long-term complications in paediatric patients. Dr Irfan at OAIC and coordinates with paediatric specialists when the child needs pain management or multidisciplinary care.

fjsfjfszj